Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism (original) (raw)
Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes
Pernille Bøttger
Clinical Genitourinary Cancer, 2019
View PDFchevron_right
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib
Michael Sawyer
Cancer Chemotherapy and Pharmacology, 2009
View PDFchevron_right
Oncology Drug Dosing in Gilbert's Syndrome Associated With UGT1A1: A Summary of the Literature
Vincent Ha
Pharmacotherapy, 2017
View PDFchevron_right
Sorafenib is an Inhibitor of UGT1A1 but is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
William Dahut
2012
View PDFchevron_right
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
Yanzhi Hsu
Leukemia, 2007
View PDFchevron_right
The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine
Joachim Maus, Ullrich Munzel
The Pharmacogenomics Journal, 2006
View PDFchevron_right
A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia
Linda McCarthy
The Pharmacogenomics Journal
View PDFchevron_right
UGT1A1*28 and *6 polymorphisms and nilotinib-induced unconjugated hyperbilirubinemia in a Japanese patient with chronic myelogenous leukemia
Yusuke Kamihara, Masayoshi Kobune
International Cancer Conference Journal, 2012
View PDFchevron_right
Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer
Rory Remmel
Oncogene, 2006
View PDFchevron_right
The polymorphism c.-3279T>G in the phenobarbital-responsive enhancer module of the bilirubin UDP-glucuronosyltransferase gene is associated with Gilbert syndrome
Elísio Costa
Clinical chemistry, 2005
View PDFchevron_right
Reversible Grade 4 Hyperbilirubinemia in a Patient with UGT1A1 7/7 Genotype Treated with Irinotecan and Cetuximab
Charles Levea
Clinical Colorectal Cancer, 2007
View PDFchevron_right
Uridine 5´-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy
jacqueline ramirez
Future Oncology, 2010
View PDFchevron_right
Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene
Peter Jansen
Journal of Hepatology, 2000
View PDFchevron_right
Molecular signature of response to pazopanib salvage therapy for urothelial carcinoma
marco alessandro pierotti
Clinical Genitourinary Cancer, 2016
View PDFchevron_right
Gilbert's Syndrome and Irinotecan Toxicity: Combination with UDP-Glucuronosyltransferase 1A7 Variants Increases Risk
thomas zwingers
Cancer Epidemiology Biomarkers & Prevention, 2008
View PDFchevron_right
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer
wataru yamamoto
Cancer Science, 2006
View PDFchevron_right
UGT1A1 (TA)n promoter genotype: Diagnostic and population pharmacogenetic marker in Serbia
Zoran Leković
Balkan Journal of Medical Genetics, 2018
View PDFchevron_right
Gilbert’s syndrome and hyperbilirubinemia in protease inhibitor therapy – An extended haplotype of genetic variants increases risk in indinavir treatment
Jürgen Rockstroh
Journal of Hepatology, 2009
View PDFchevron_right
Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity
Alain Morel
Clinical Cancer Research, 2004
View PDFchevron_right
Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
Dimitrios Paraskevis
Pharmacogenomics and personalized medicine, 2017
View PDFchevron_right
Genetic Polymorphisms of the UDP-Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients
Ross McKinnon
Cancer Science, 2002
View PDFchevron_right
Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity
Alfredo Carrato
JCO Oncology Practice, 2022
View PDFchevron_right
UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Isabelle Soubeyran
2007
View PDFchevron_right
Frequency of dihydropyrimidine dehydrogenase and UDP-glucuronosyltransferase 1A1 variants in cancer patients requiring chemotherapy: A single-center study in southern India
Qurratulain Hasan, JCBR jcbr, Kevin Gangavarapu
Journal of Clinical and Basic Research (JCBR), 2023
View PDFchevron_right
Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert's syndrome mutations in UGT1A1
Marcello Persico
Hepatology, 2001
View PDFchevron_right
Polymorphisms of the UDP-Glucuronosyl Transferase 1A Genes Are Associated with Adverse Events in Cancer Patients Receiving Irinotecan-Based Chemotherapy
Masataka Kikuyama
The Tohoku Journal of Experimental Medicine, 2013
View PDFchevron_right
Tyrosine kinase inhibitor resistance: a case report on chronic myeloid leukemia and Gilbert’s syndrome
Fernanda Roversi
AME Case Reports
View PDFchevron_right
Donor Liver Uridine Diphosphate (UDP)-GLUCURONOSYLTRANSFERASE-1A1 Deficiency Causing Gilbert???S Syndrome in Liver Transplant RECIPIENTS12
Helen Te
Transplantation, 2000
View PDFchevron_right
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis
Helmut Friess
Cancer research, 2000
View PDFchevron_right
Detrimental Eeffect of Atazanavir Plasma Concentrations on Total Serum Bilirubin Levels in the Presence of UGT1A1 Polymorphisms
gianlodovico melzi d'eril
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
View PDFchevron_right
Frequency of the UGT1A1*28 Polymorphism in a Romanian Cohort of Gilbert Syndrome Individuals
Elena Poenaru
Journal of gastrointestinal and liver diseases : JGLD, 2017
View PDFchevron_right
The UGT1A1∗28 polymorphism correlates with erlotinib’s effect on SN-38 glucuronidation
Larry House
European Journal of Cancer, 2010
View PDFchevron_right
Non tumoral hyperserotoninaemia responsive to octreotide due to dual polymorphism in UGT1A1 and UGT1A6
Kalliopi Kotsa
Hormones (Athens, Greece)
View PDFchevron_right
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
Gustaaf Dekker
The lancet oncology, 2011
View PDFchevron_right
Gilbert Syndrome and the Development of Antiretroviral Therapy–Associated Hyperbilirubinemia
Hansjakob Furrer
The Journal of Infectious Diseases, 2005
View PDFchevron_right